Skip to main content

Day: September 25, 2020

Bergman & Beving AB: Share-based incentive scheme

Press releaseShare-based incentive schemeThe share-based incentive scheme resolved by the 2020 Annual General Meeting where around 20 members of senior management were offered to acquire up to 244,000 call options on repurchased class B shares has been fully subscribed.The call options will be transferred at a price of SEK 4.96 per call option, equivalent to the market value according to an external independent valuation, applying the Black-Scholes-model. The redemption price of the call options amounts to SEK 99.50, equivalent to 120 percent of the volume-weighted average of the paid market price for the shares during the period from 27 August to 9 September 2020, inclusive. Each call option entitles the holder to acquire one repurchased class B share during the period from 11 September 2023 to 7 June 2024, inclusive.Stockholm, 25 September...

Continue reading

Bergman & Beving AB: Aktierelaterat incitamentsprogram

PressmeddelandeAktierelaterat incitamentsprogramDet av årsstämman 2020 beslutade aktierelaterade incitamentsprogrammet som omfattar cirka 20 ledningspersoner om maximalt 244 000 köpoptioner på återköpta aktier av serie B har fulltecknats.Köpoptionerna kommer att överlåtas till ett pris av 4,96 SEK per köpoption vilket motsvarar marknadsvärdet enligt en extern oberoende värdering utförd i enlighet med Black-Scholes-modellen. Lösenkursen för köpoptionerna uppgår till 99,50 SEK motsvarande 120 procent av den genomsnittliga aktiekursen under mätperioden 27 augusti – 9 september 2020. Varje köpoption berättigar till förvärv av en återköpt aktie av serie B under perioden från och med den 11 september 2023 till och med den 7 juni 2024.Stockholm den 25 september 2020Bergman & Beving AB (publ)För ytterligare information kontakta:Peter Schön,...

Continue reading

Nominating committee ahead of Industrivärden’s 2021 AGM

In accordance with a resolution for the Nominating Committee made by the 2011 Annual General Meeting, and which applies until further notice, the Chairman of the Board is assigned the task of contacting four shareholders from among the largest registered shareholders in terms of votes in Euroclear Sweden AB’s printout of the shareholder register as per the last business day in August, who each appoints one representative who is not a director on the Company’s board, to form together with the Chairman of the Board a Nominating Committee for the time until a new Nominating Committee has been appointed. The Nominating Committee appoints a committee chair from among its members. The composition of the Nominating Committee shall be made public not later than six months before the next Annual General Meeting. No fee is payable for...

Continue reading

Valberedning inför Industrivärdens årsstämma 2021

Enligt det beslut om valberedningen som fattades vid årsstämman 2011, och som gäller tillsvidare, uppdras åt styrelsens ordförande att ta kontakt med fyra bland de röstmässigt största ägarregistrerade aktieägarna i Euroclear Sweden AB:s utskrift av aktieboken per sista bankdagen i augusti, som vardera utser en representant som inte är ledamot i bolagets styrelse att jämte ordföranden utgöra valberedning för ti-den intill dess att ny valberedning utsetts. Valberedningen utser ordföranden inom gruppen. Sammansättningen av valberedningen ska tillkännages senast sex månader före nästa årsstämma. Inget arvode ska utgå.I enlighet härmed har valberedningen följande sammansättning: Mats Guldbrand, L E Lundbergföretagen, Stefan Nilsson, Handelsbankens Pensionsstiftelse m fl, Mikael Schmidt, SCA och Essity Pensionsstiftelser m fl, Bo Damberg, Jan...

Continue reading

Orphazyme A/S provides update on previously announced global offering

Orphazyme A/SCompany announcement                                                                                       No. 54/2020                                                                                                          Company Registration No. 32266355 Copenhagen, Denmark, September 25, 2020 – Orphazyme A/S (ORPHA.CO) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced an update on its previously announced global offering. On September 24, 2020, the Company received a filing communication from the U.S. Food and Drug Administration (FDA) in connection with its new drug application (NDA) for arimoclomol for the treatment of Niemann-Pick disease Type C. The FDA letter follows acceptance on a Priority Review...

Continue reading

Victory Square Technologies Portfolio Company Acquires Brazilian Manufacturing & Laboratory Facility to Increase Production of its Covid-19 Testing Products by an additional 4,000,000 Units in Brazil

Allows for further research and production of up to 4,000,000 additional testing units per month for Safetest following ANVISA (Brazilian Health Authority) approvals that apply to the laboratory and production facility onlyThe Company has already received ANVISA approvals for the sale and distribution of its proprietary Safetest ELISA Covid-19 testThis will increase laboratory testing and production of Safetest products in South America and globallyVANCOUVER, British Columbia, Sept. 25, 2020 (GLOBE NEWSWIRE) — Victory Square Health Inc. (“VS Health” or the “Company”) – a portfolio company of Victory Square Technologies Inc. (“Victory Square”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) – has entered into an agreement on September 24, 2020 to acquire a certified laboratory and production facility in Minas Gerais, Brazil. This acquisition will...

Continue reading

Composition of Lassila & Tikanoja plc’s Nomination Board

Lassila & Tikanoja plcStock exchange release25 September 2020 at 10:00Composition of Lassila & Tikanoja plc’s Nomination BoardLassila & Tikanoja plc’s three largest shareholders, who are determined on the basis of the shareholder register held by Euroclear as per 1 September 2020 and who are shareholders acting according to the principles otherwise mentioned in the Charter, are entitled to appoint their representatives to the company’s Nomination Board. According to the Charter of the Nomination Board, a group of shareholders may agree on the appointment of a joint representative to the Nomination Board. The following shareholders have agreed on the appointment of a joint representative: Chemec Oy, Maijala Eeva, Maijala Hannele, Maijala Heikki, Maijala Juhani, Maijala Juuso, Maijala Miikka, Maijala Mikko, Maijala Roope...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.